This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Reasons to Add ABT Stock to Your Portfolio Right Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM
by Zacks Equity Research
TMO launches the Krios 5 Cryo-TEM, boosting productivity and performance with enhanced automation.
Abbott (ABT) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $131.63, representing a -0.23% change from its previous close.
Global Expansion in EPD and Innovations Support Abbott Stock
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Has EUROFINS SCIENT (ERFSF) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how EUROFINS SCIENT (ERFSF) and Abbott (ABT) have performed compared to their sector so far this year.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ABT Stock to Gain From Early CE Mark Approval of Volt PFA System
by Zacks Equity Research
Abbott achieves early CE Mark approval for the Volt PFA system.
ABT Stock Gains Following the Positive TRILUMINATE Trial Results
by Zacks Equity Research
Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.
Abbott (ABT) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $132.65, marking a +1.4% move from the previous day.
GE HealthCare's Latest Product Launch to Boost Cardiology Care
by Zacks Equity Research
GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
by Zacks Equity Research
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
by Zacks Equity Research
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology
by Zacks Equity Research
McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology are part of the Zacks top Analyst Blog.
Top Research Reports for McDonald's, Abbott & O'Reilly Automotive
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including McDonald's Corp. (MCD), Abbott Laboratories (ABT) and O'Reilly Automotive, Inc. (ORLY), as well as a micro-cap stock MIND Technology, Inc. (MIND).
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of 0% and 1.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
by Urmimala Biswas
Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
by Zacks Equity Research
Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic
by Zacks Equity Research
Boston Scientific, Abbott and Medtronic are included in this Analyst Blog.
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Abbott (ABT) reachead $127.21 at the closing of the latest trading day, reflecting a +0.69% change compared to its last close.
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
by Urmimala Biswas
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
by Nalak Das
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -8.70% and 57.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the most recent trading session, Abbott (ABT) closed at $127.42, indicating a +0.89% shift from the previous trading day.